Global Non Small Cell Lung Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 1,291.66 Million |
 Market Size (Forecast Year) |
USD 3,463.37 Million |
 CAGR |
% |
| Major Markets Players |
|
全球非小细胞肺癌市场，按癌症类型（肺腺癌（LUAD）、肺鳞状细胞癌（LUSC）、大细胞癌等）、产品（试剂和试剂盒、仪器、服务和软件）测试（影像测试、分子测试、活检、痰细胞学、胸腔穿刺术、免疫组织化学等）、最终用户（医院、临床实验室、学术界等）国家（美国、墨西哥、加拿大、法国、俄罗斯、荷兰、英国、德国、意大利、西班牙、土耳其、比利时、瑞士和欧洲其他地区、中国、泰国、澳大利亚、日本、韩国、新加坡、马来西亚、印度尼西亚、菲律宾、印度和亚太其他地区、南非、埃及、沙特阿拉伯、阿联酋、以色列和中东和非洲其他地区、巴西、阿根廷南美洲其他地区）行业趋势和预测到 2028 年。
市场分析与洞察：全球非小细胞肺癌诊断市场
全球非小细胞肺癌诊断市场规模预计将从 2020 年的 12.9166 亿美元增至 2028 年的 34.6337 亿美元，在 2021 年至 2028 年的预测期内以 13.2% 的复合年增长率稳步增长。
非小细胞肺癌是一种在肺组织中形成恶性细胞或癌细胞的疾病。这些细胞有不同的类型，每种类型的癌细胞都不同，并且生长和扩散的方式也不同。非小细胞肺癌 (NSCLC) 的类型包括鳞状细胞癌、大细胞癌和腺癌。鳞状细胞癌的癌症形成于肺内壁薄而扁平的细胞中，称为表皮样癌。大细胞癌始于几种类型的大细胞。腺癌始于肺泡内壁细胞，并产生粘液等物质。非小细胞肺癌 (NSCLC) 的主要风险之一是吸烟，症状包括持续咳嗽和呼吸急促。人们使用各种测试来诊断和检查癌症阶段，例如影像学测试、分子测试、活检等。诊断对于及时发现疾病至关重要，这样才能对患者进行适当的治疗。
推动非小细胞肺癌诊断市场增长的因素包括人工智能和机器学习的使用，以改进诊断程序，以及更容易患非小细胞肺癌的老年人口数量的增加。另一方面，仪器的高成本和与品牌资产相关的挑战可能会阻碍非小细胞肺癌诊断市场的增长。
The rising healthcare expenditure in developing regions will create opportunities for the non-small cell lung cancer diagnostics market. However, the high competition among market players is acting as one of the challenges to the growth non-small cell lung cancer diagnostics market.
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Global Non-Small Cell Lung Cancer Diagnostics Market Scope And Market Size
The global non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing cases of lung adenocarcinoma worldwide.
- On the basis of products, the non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the rise in the usage of different instruments for diagnostic purposes in cancer.
- On the basis of tests, the non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing molecular test for diagnostic purposes.
- On the basis of end-users, the non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing clinical research in cancer.
Global Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
The global non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the global Non-small cell lung cancer diagnostics market report are the U.S., Mexico, Canada, France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland, and the rest of Europe, China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and rest of Asia-Pacific, South Africa Egypt, Saudi Arabia, UAE, Israel, and rest of the Middle East and Africa, Brazil, Argentina Rest of South America.
China, U.S., and Germany are dominating the global non-small cell lung cancer diagnostics market. The U.S. is expected to dominate the non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer. China is expected to dominate the non-small cell lung cancer diagnostics market due to the growing usage of artificial intelligence for diagnostic purposes. Germany is expected to dominate the non-small cell lung cancer diagnostics market due to the growing geriatric population that is more prone to developing lung cancer
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Rising Demand For Diagnostic In The Medical Setting
The global non-small cell lung cancer diagnostics market also provides you with detailed market analysis for every country's growth in the industry with sales, components sales, the impact of technological development in IORT, and changes in regulatory scenarios with their support for the IORT market. The data is available for the historic period 2010 to 2019.
Competitive Landscape And Global Non-Small Cell Lung Cancer Diagnostics Market Share Analysis
Global non-small cell lung cancer diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies' focus related to the non-small cell lung cancer diagnostics market.
非小细胞肺癌诊断市场的一些主要参与者包括雅培实验室、罗氏有限公司、安捷伦科技公司、凯杰公司、赛默飞世尔科技公司、Quest Diagnostics Incorporated、NeoGenomics Laboratories, Inc.、NanoString、杨森制药、Inivata Ltd、bioMérieux SA、Biotheranostics、OncoCyte Corporation Inc.、通用电气公司、Eckert & Ziegler、Dr. Lal PathLabs、RIVERAIN TECHNOLOGIES、PlexBio Co., Ltd、Oncimmune、Biodesix 等。
全球非小细胞肺癌诊断市场比较分散，主要参与者采用合作、认可、协议等各种策略来扩大其在非小细胞肺癌诊断市场的影响力。
例如，
- 2021 年 3 月，安捷伦科技公司以 5.5 亿美元收购了 Resolution Bioscience，以加强其基于下一代测序 (NGS) 的肿瘤学解决方案业务。
- 2021 年 5 月，QIAGEN 推出了经 FDA 批准的 therascreen KRAS RGQ PCR 试剂盒，该试剂盒可帮助患者识别非小细胞肺癌 (NSCLC)
- 2020年6月，罗氏公司推出自动化数字病理算法uPath PD-L1（SP263）图像分析，用于诊断非小细胞肺癌（NSCLC），提高诊断治疗的速度和准确性
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 CANCER TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
4.2 PRODUCT AND BRAND ANALYSIS: GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
4.3 ABBOTT LABORATORIES-
4.4 F. HOFFMANN-LA ROCHE LTD -
4.5 AGILENT TECHNOLOGIES, INC.
4.6 QIAGEN
4.7 THERMO FISHER SCIENTIFIC, INC
4.8 QUEST DIAGNOSTICS INCORPORATED
4.9 NEOGENOMICS LABORATORIES, INC.
4.1 NANOSTRING
4.11 JANSSEN PHARMACEUTICAL NV
4.12 INIVATA LTD
4.13 BIOMÉRIEUX SA
4.14 BIOTHERANOSTICS, INC.
4.15 ONCOCYTE CORPORATION
4.16 ECKERT & ZIEGLER
4.17 GENERAL ELECTRIC COMPANY
4.18 DR LAL PATHLABS
4.19 RIVERAIN TECHNOLOGIES
4.2 PLEXBIO CO.,LTD
4.21 BIODESIX
4.22 ONCIMMUNE
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF LUNG CANCER ACROSS THE WORLD
5.1.2 GROWING NUMBER OF GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER
5.1.3 GROWING COLLABORATION PARTNERSHIP AND AGREEMENT BY THE KEY PLAYERS
5.1.4 GROWING USAGE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO IMPROVE THE DIAGNOSTIC PROCEDURES
5.1.5 INCREASING PREVALENCE OF UNHEALTHY LIFESTYLE THAT POSES A SERIOUS RISK OF LUNG CANCER
5.1.6 GROWING PRODUCT LAUNCHES
5.2 RESTRAINTS
5.2.1 CHALLENGES ASSOCIATED WITH BRAND EQUITY
5.2.2 MAINTAINING HIGH LEVEL OF EXPERTISE FOR DIAGNOSIS PURPOSE
5.3 OPPORTUNITIES
5.3.1 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
5.3.2 INCREASING ADOPTION OF NEW TECHNOLOGY TO DIAGNOSE NON-SMALL CELL LUNG CANCER
5.3.3 INCREASE IN THE NUMBER OF APPROVALS FOR NON-SMALL CELL LUNG CANCER PRODUCTS
5.4 CHALLENGES
5.4.1 HIGH COMPETITION AMONG MARKET PLAYERS
5.4.2 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE GLOBAL NON SMALL CELL LUNG CANCER DIAGNOSTIC MARKET
6.1 IMPACT ON DEMAND
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON PRICE
6.4 CONCLUSION
7 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE
7.1 OVERVIEW
7.2 LUNG ADENOCARCINOMA (LUAD)
7.3 LUNG SQUAMOUS CELL CARCINOMA (LUSC)
7.4 LARGE CELL CARCINOMA
7.5 OTHERS
8 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 REAGENTS AND KITS
8.3.1 LUNG CANCER ASSAY KIT
8.3.2 MUTATION KIT
8.3.3 EXTRACTION KIT
8.3.4 SAMPLE PREPARATION KIT
8.3.5 SOLID TUMOUR KIT
8.3.6 OTHERS
8.4 SERVICES AND SOFTWARES
9 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST
9.1 OVERVIEW
9.2 MOLECULAR TEST
9.2.1 RT-PCR
9.2.2 NEXT-GENERATION SEQUENCING (NGS)
9.2.3 DNA MICROARRAY
9.2.4 NEXT GENERATION CAPTURE
9.2.5 LAB-ON -A CHIP (LOAC)
9.2.6 MULTIPLEX CONVENTIONAL
9.2.7 PROTEIN MICROARRAY
9.2.8 OTHER
9.3 IMAGING TEST
9.3.1 PISITRON EMISSION TOMOGRAPHY (PET) SCAN
9.3.2 MAGNETIC RESONANCE IMAGING (MRI) SCAN
9.3.3 CT SCAN
9.3.4 BONE SCAN
9.3.5 OTHERS
9.4 IMMUNOHISTOCHEMISTRY
9.5 BIOPSY
9.6 SPUTUM CYTOLOGY
9.7 THORECENTESIS
9.8 OTHERS
10 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
10.5 INSTITUTES AND RESEARCH CENTERS
11 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION
11.1 GLOBAL MARKET
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 ASIA-PACIFIC
11.6.1 CHINA
11.6.2 JAPAN
11.6.3 INDIA
11.6.4 SOUTH KOREA
11.6.5 AUSTRALIA
11.6.6 MALAYSIA
11.6.7 THAILAND
11.6.8 INDONESIA
11.6.9 SINGAPORE
11.6.10 PHILIPPINES
11.6.11 REST OF ASIA-PACIFIC
11.7 EUROPE
11.7.1 GERMANY
11.7.2 FRANCE
11.7.3 ITALY
11.7.4 RUSSIA
11.7.5 U.K.
11.7.6 SPAIN
11.7.7 TURKEY
11.7.8 SWITZERLAND
11.7.9 BELGIUM
11.7.10 NETHERLANDS
11.7.11 REST OF EUROPE
11.8 MIDDLE EAST AND AFRICA
11.8.1 SAUDI ARABIA
11.8.2 ISRAEL
11.8.3 SOUTH AFRICA
11.8.4 UAE
11.8.5 EGYPT
11.8.6 REST OF MIDDLE EAST AND AFRICA
11.9 SOUTH AMERICA
11.9.1 BRAZIL
11.9.2 ARGENTINA
11.9.3 REST OF SOUTH AMERICA
12 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 QUEST DIAGNOSTICS INCORPORATED
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 GENERAL ELECTRIC COMPANY
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NANOSTRING
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BIODESIX
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BIOMERIEUX SA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 BIOTHERANOSTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DR LAL PATHLABS
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 ECKERT & ZIEGLER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 INIVATA LTD
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JANSSEN PHARMACEUTICAL NV
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 NEOGENOMICS LABORATORIES, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 ONCIMMUNE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 ONCOCYTE CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 PLEXIBIO CO LTD
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 QIAGEN
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 RIVERAIN TECHNOLOGIES
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 AGING WORLD POPULATION
TABLE 2 U.K. X RAY DEMAND 2018
TABLE 3 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 4 GLOBAL LUNG ADENOCARCINOMA (LUAD) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 GLOBAL LUNG SQUAMOUS CELL CARCINOMA (LUSC) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 GLOBAL LARGE CELL CARCINOMA IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 GLOBAL OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 9 GLOBAL INSTRUMENTS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 GLOBAL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 GLOBAL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 12 GLOBAL SERVICES AND SOFTWARES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 14 GLOBAL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 GLOBAL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 16 GLOBAL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 GLOBAL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 18 GLOBAL IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 GLOBAL BIOPSY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2020
TABLE 20 GLOBAL SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 GLOBAL THORECENTESIS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 GLOBAL OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 24 GLOBAL CLINICAL LABORATORIES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 GLOBAL HOSPITAL IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 GLOBAL ACADEMICS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 GLOBAL INSTITUTES AND RESEARCH CENTERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 37 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 38 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 39 U.S. NON-SMALL REAGENTS AND KITS IN CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 40 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 41 U.S. IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 42 U.S. MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 43 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 44 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 45 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 CANADA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 47 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 48 CANADA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 49 CANADA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 50 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 51 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 52 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 MEXICO REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 54 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 55 MEXICO IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 56 MEXICO MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 57 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 67 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 CHINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 69 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 70 CHINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 71 CHINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 72 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 74 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 75 JAPAN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 76 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 77 JAPAN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 78 JAPAN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 79 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 81 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 82 INDIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 83 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 84 INDIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 85 INDIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 86 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 87 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 88 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 89 SOUTH KOREA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 90 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 91 SOUTH KOREA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 92 SOUTH KOREA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 93 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 95 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 AUSTRALIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 97 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 98 AUSTRALIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 99 AUSTRALIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 100 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 102 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 103 MALAYSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 104 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 105 MALAYSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 106 MALAYSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 107 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 108 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 109 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 110 THAILAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 111 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 112 THAILAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 113 THAILAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 114 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 115 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 116 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 117 INDONESIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 118 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 119 INDONESIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 120 INDONESIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 121 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 123 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 124 SINGAPORE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 126 SINGAPORE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 127 SINGAPORE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 128 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 129 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 130 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 131 PHILIPPINES REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 132 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 133 PHILIPPINES IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 134 PHILIPPINES MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 135 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 136 REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 137 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 138 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 139 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 EUROPE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 142 EUROPE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 143 EUROPE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 144 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 145 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 146 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 147 GERMANY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 148 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 149 GERMANY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 150 GERMANY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 151 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 152 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 153 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 154 FRANCE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 156 FRANCE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 157 FRANCE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 158 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 159 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 160 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 161 ITALY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 162 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 163 ITALY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 164 ITALY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 165 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 166 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 167 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 168 RUSSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 169 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 170 RUSSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 171 RUSSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 172 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 173 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 174 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 175 U.K. REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 176 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 177 U.K. IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 178 U.K. MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 179 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 180 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 181 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 182 SPAIN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 183 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 184 SPAIN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 185 SPAIN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 186 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 187 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 188 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 189 TURKEY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 190 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 191 TURKEY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 192 TURKEY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 193 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 194 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 195 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 196 SWITZERLAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 197 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 198 SWITZERLAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 199 SWITZERLAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 200 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 201 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 202 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 203 BELGIUM REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 204 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 205 BELGIUM IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 206 BELGIUM MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 207 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 208 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 209 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 210 NETHERLANDS REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 211 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 212 NETHERLANDS IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 213 NETHERLANDS MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 214 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 215 REST OF EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 216 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 217 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 218 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 220 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 222 MIDDLE EAST & AFRICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 224 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 225 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 226 SAUDI ARABIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 228 SAUDI ARABIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 229 SAUDI ARABIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 230 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 231 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 232 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 233 ISRAEL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 234 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 235 ISRAEL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 236 ISRAEL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 237 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 238 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 239 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 240 SOUTH AFRICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 241 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 242 SOUTH AFRICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 243 SOUTH AFRICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 244 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 245 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 246 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 247 UAE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 248 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 249 UAE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 250 UAE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 251 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 252 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 253 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 254 EGYPT REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 255 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 256 EGYPT IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 257 EGYPT MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 258 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 259 REST OF MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 260 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 261 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 262 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 263 SOUTH AMERICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 264 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 265 SOUTH AMERICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 266 SOUTH AMERICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 267 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 268 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 269 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 270 BRAZIL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 271 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 272 BRAZIL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 273 BRAZIL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 274 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 275 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 276 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 277 ARGENTINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 278 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 279 ARGENTINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 280 ARGENTINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 281 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 282 REST OF SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
图片列表
LIST OF FIGURES
FIGURE 1 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 RISE IN THE GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER IS EXPECTED TO DRIVE THE GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR NON-SMALL CELL LUNG CANCER DIAGNOSTICS MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
FIGURE 15 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2020
FIGURE 16 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 17 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2020
FIGURE 18 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 19 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 20 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY REGION (2020)
FIGURE 21 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY REGION (2021 & 2028)
FIGURE 22 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY REGION (2020 & 2028)
FIGURE 23 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 24 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 25 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 26 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 27 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 28 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 29 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 30 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 31 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 32 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 33 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 34 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 35 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 36 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 37 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 38 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 39 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 40 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 41 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 42 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 43 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 44 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 45 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 46 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 49 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
FIGURE 50 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
FIGURE 51 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
FIGURE 52 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
